Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

This study found that the polyherbal cough syrup Linkus reduced cough reflexes without causing observed toxicity in rats, suggesting it may be an effective and safe option.

In this study, researchers found that retinoids might improve lupus nephritis resistant to conventional treatments, but the sample size was too small for significant results, and side effects were noted.

This review discusses the guidelines for using and monitoring mood stabilizers in bipolar disorders, highlighting that only a minority of patients receive guideline-adherent monitoring.

Lamotrigine can cause hair loss in some patients.

This case report describes a 14-year-old boy who developed toxic epidermal necrolysis, involving over 30% of his body surface, following treatment with amoxicillin-clavulanate, cefuroxime, and lamotrigine.

This article discusses the potential of low-dose naltrexone as an adjuvant therapy for trichodynia in alopecias, noting its anti-inflammatory properties and need for further research.

This study concluded that adding Kanglaite injection to gemcitabine and cisplatin chemotherapy for advanced non-small cell lung cancer improved response rates and reduced adverse side effects.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

Results are not reported in this article by Zizhuo Li et al. on baricitinib as a treatment for lichen planopilaris.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

This review suggests that bendamustine, alone or in combination, shows effectiveness in treating indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, with recent studies highlighting its benefits especially in combination therapies, while balancing efficacy with a favorable toxicity profile.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

This case report describes a patient who developed a maculopapular rash after starting lithium treatment, highlighting the importance of monitoring skin reactions due to potential impact on treatment adherence.

This study found that the nanostructured lipid carrier formulation with a 70:30 solid to liquid lipid ratio significantly increased the dissolution rate, entrapment efficiency, and stability of spironolactone compared to its raw form.

This study found that naltrexone did not significantly reduce hair pulling in adults with trichotillomania compared to placebo, although it improved cognitive flexibility.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

This study found that switching patients with glaucoma or ocular hypertension from benzalkonium chloride-latanoprost to preservative-free latanoprost maintained intraocular pressure control and improved tolerability, potentially enhancing treatment adherence and quality of life.

Tiny particles carrying roxithromycin can effectively target and deliver the drug to hair follicles without irritation.

In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

This study discovered that the disposition of LY191704 enantiomers in rats and dogs is both stereoselective and species specific.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

The researchers reported that low-dose methotrexate, in combination with surgical dilatation and local treatments, may improve symptoms in patients with severe stenosing vulvovaginal lichen planus.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.